Publication date: 11/09/2018
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART) announces today that its board of directors created, within the framework of the authorized capital, 1,335,426 warrants under a new warrant plan, called the 'Warrant Plan 2018', in order to enable the Company to offer the warrants to mainly certain selected employees of the Company and its subsidiaries, as well as to consultants of the Company and its subsidiaries, independent directors of the Company and directors of the Company's subsidiaries.
The warrants under the Warrant Plan 2018 have an exercise term of ten years (unless contractually reduced in the offer to a beneficiary), are generally not transferable and can in principle not be exercised prior to the first day of the fourth calendar year following the calendar year in which the offer of warrants is accepted by a beneficiary. Each warrant gives the right to subscribe to one new Biocartis share. Should the warrants be exercised, Biocartis will apply for the admission to trading of the resulting new shares on Euronext Brussels. The warrants as such will not be listed on any stock market.
The special reports prepared by the board of directors (in accordance with Articles 583, 596 and 598 of the Belgian Companies Code) and the Company's statutory auditor (in accordance with Articles 596 and 598 of the Belgian Companies Code) in the framework of the creation of the Warrant Plan 2018 can be consulted on the website of the Company.
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers fifteen oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.